Form S-8 Jazz Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Jazz Pharmaceuticals (JAZZ) PT Lowered to $187 at BMO Capital
March 2, 2022 7:47 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $187.00 (from $202.00) while maintaining an Outperform rating following results.
The analyst commented, "4Q beat top- and bottom-line solidly, mainly driven by Epidiolex/Rylaze growth (also stocking) and continued progress with... More
